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A B S T R A C T
Data concerning the clinical and epidemiological
features of travel-associated cryptosporidiosis are
lacking. In order to investigate the impact of this
disease on travellers’ health, a retrospective study
was conducted at the Institute of Tropical Medi-
cine, Berlin. In total, 57 cryptosporidial infections
were identified between 2000 and 2004, resulting
in a prevalence of 2.9% in patients with travel-
associated diarrhoea. Travel to south-central Asia,
especially India, was associated with a higher
prevalence of infection than was travel to other
destinations. Clinically, the disease resembled
giardiasis, but fever and arthralgias seemed to
occur more frequently.
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Infections caused by Cryptosporidium spp. are
gaining increasing attention as an emerging
infectious disease [1]. Cryptosporidia are recog-
nised primarily for their ability to cause water-
and foodborne outbreaks and serious opportun-
istic infection in immunocompromised patients.
However, most infections occur as sporadic
cases in immunocompetent individuals [2], in
whom infections are usually self-limited,
although prolonged courses, relapses and extra-
intestinal sequelae have been observed in up to
40% of cases [3]. Travel abroad is a known risk-
factor for sporadic cryptosporidiosis [2,4,5], but
although cryptosporidia are among the parasites
isolated frequently from travel-associated intes-
tinal infections [6], relatively few data are
available concerning the prevalence, risk
and clinical presentation of cryptosporidiosis in
travellers.
This study describes 57 cases of imported
cryptosporidiosis diagnosed at the Institute of
Tropical Medicine, Berlin (IfT) between 2000 and
2004. All patients had a recent history of interna-
tional travel and were not known to be HIV-
positive or otherwise immunocompromised.
Except for three pairs of patients who acquired
cryptosporidiosis while travelling together, no
clusters of infection were identified. Clinical and
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epidemiological data were obtained retrospec-
tively from medical records. At least one stool
sample from each patient was examined. Cryptos-
poridium spp. and Giardia lamblia were diagnosed
using a direct immunofluorescence assay based
on monoclonal antibodies (Merifluor Crypto &
Giardia; Meridian Bioscience, Cincinnati, OH,
USA). Cryptosporidium-positive samples were con-
firmed by Kinyoun acid-fast stain [7]. Other
intestinal protozoa were detected by microscop-
ical examination of native and concentrated stool
specimens. Depending on the clinical presenta-
tion and travel destination, investigations for
other infectious diseases, such as malaria, dengue
fever and viral hepatitis, were performed. During
the study period, 1754 travellers attended the IfT
with diarrhoea and tested negative for cryptospo-
ridiosis. These patients served as controls to
calculate associations for travel-related crypto-
sporidiosis. Data were analysed by SAS v.8.01
(SAS Institute, Cary, NC, USA).
Among the 57 patients with cryptosporidiosis,
one patient had co-infection with dengue virus,
while another patient suffered from shigellosis;
other enteric parasites were detected in 17
patients (G. lamblia 9, Blastocystis hominis 7, End-
olimax nana 6, Entamoeba dispar 5, Entamoeba coli 4,
Iodamoeba bu¨tschlii 2 and Chilomastix mesnili 2).
The patients suffering from dengue fever, shigel-
losis or giardiasis were excluded from the follow-
ing analysis of clinical and laboratory features.
Most (91%) of the patients with cryptosporidiosis
presented with diarrhoea as the main symptom.
Other symptoms included abdominal pain (69%),
fatigue (56%), flatulence (40%), anorexia (31%),
fever (30%), nausea (27%), weight loss (24%),
arthralgias (15%), vomiting (13%) and headache
(13%). Fever usually occurred for a short duration
during the first days of clinical symptoms. The
median duration of symptoms was 16 (range 3–
60) days. There was a slight increase (median 1.4-
fold) in the levels of one or more liver enzymes in
31% of cases. C-reactive protein levels were
elevated (median 2.2-fold) in 52% of patients.
Among the patients, 56% were female, the
median age was 31 (range 14–66) years, and the
median travel duration was 25 (range 8–346)
days. Most patients were individual travellers
(backpackers 51.5%; visiting friends or family
12.1%) or reported an occupational stay abroad
(12.1%). The infections originated from 31 differ-
ent countries, with most cases being acquired in
Asia, followed by Africa, Latin America and
Europe (Table 1). The vast majority of Asian cases
(61.3%) derived from India.
To rank the geographical risk, travel destina-
tions of patients with diarrhoea caused by cryp-
tosporidiosis were compared with those of
patients with other types of travel-associated
diarrhoea (Table 2). Cryptosporidia were present
in 2.9% of all patients with traveller’s diarrhoea,
and were more frequent in patients with diar-
rhoea returning from Asia than in those returning
from Africa (OR 2.7, 95% CI 1.3–5.7). In Asia, the
frequency of cryptosporidiosis was higher in
patients returning from south-central than from
south-eastern Asia (OR 3.0, 95% CI 1.2–7.6). There
was no significant difference in the duration of
travel for patients with diarrhoea with and with-
out cryptosporidiosis (median 22 vs. 25 days;
p 0.589). This analysis was not performed for
patients returning from European and north
American destinations because such patients
rarely attend Tropical Medicine institutions and
were therefore not represented adequately.
Table 1. Travel destinations of patients with cryptospo-
ridiosis (multiple entries possible)
Geographical area
Patients with cryptosporidiosis
n = 57 %
Asia 31 54.4
India 19
Thailand 5
Nepal 3
Cambodia 2
Malaysia 2
Syria 2
Turkey 2
Lebanon 1
Vietnam 1
Africa 12 21.1
Egypt 3
Mauritius 2
Ethiopia 1
Benin 1
Burkina Faso 1
Cameroon 1
Kenya 1
Mali 1
Senegal 1
Tanzania 1
America 11 19.3
Dominican Republic 2
Ecuador 2
Peru 2
Argentina 1
Bolivia 1
Brazil 1
Chile 1
Costa Rica 1
Guatemala 1
Mexico 1
Europe 3 5.3
France 2
UK 1
922 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 918–940
The cryptosporidiosis cases were correlated
with travel statistics provided by the German
Federal Statistical Office [8]. During the year 2002,
2.9 million Germans aged > 15 years travelled to
Africa, 1.4 million to Asia, and 0.8 million to Latin
America. Following extrapolation to match the
4-year study period, the cryptosporidiosis risk in
Asia and Latin America was higher than in Africa
(OR 6.9, 95% CI 3.3–14.5, and OR 4.4, 95% CI
1.8–10.7, respectively).
The present study was limited by its retrospec-
tive design, and there was an absence of stand-
ardised laboratory or clinical data for all 57
patients. Also, there may have been a bias towards
more severe or prolonged manifestations of cryp-
tosporidiosis, as all patients attended outpatient
clinics specialising in Tropical Medicine. How-
ever, the overall prevalence of cryptosporidia
among patients with travel-associated diarrhoea
was 2.9%, which agrees with previous data from
Germany [9]. The frequency of cryptosporidial
infection was higher in travellers returning from
Asia, especially from south-central Asia, and was
lower in travellers returning from African desti-
nations. Similar differences have been observed
for Spanish travellers with diarrhoea caused by
Cyclospora cayetanensis [10]. In India, wheremost of
the cases investigated were acquired, cryptospo-
ridiosis has been recognised as an important cause
of intestinal disease in children and adults [11,12],
but studies comparing the endemicity of cryptos-
poridia in various regions are lacking. Overall
diarrhoea attack rates in tourists visiting Asian
and African destinations are similar [13], suggest-
ing that conditions during journeys to Asia and
Africa do not differ significantly. However, India
and other Asian countries are popular destinations
for backpackers and other individual travellers
who are exposed to poor hygiene conditions. In
contrast, travellers visiting African countries tend
to stay in tourist resorts.
No association of cryptosporidiosis with long-
term travel was demonstrated. However, this
comparison might be confounded as the
control group consisted of travellers with
non-cryptosporidial diarrhoea presenting at a
specialised institute. In previous studies, long-
term travel has been associated with other intes-
tinal parasitic infections, such as giardiasis [14].
As the German Federal Statistical Office reports
travel for ‡ 4 weeks for only 3.4% of all German
travellers [8], compared with 46% in the present
study, it is possible that long-term travel is also a
risk-factor for cryptosporidiosis.
Clinically, travel-associated cryptosporidiosis
presented as prolonged diarrhoea, often accom-
panied by abdominal pain, fatigue and flatulence.
Laboratory examinations were unremarkable,
except for slight elevations in levels of liver
enzymes and C-reactive protein. In general, the
clinical presentation resembled that of giardiasis,
but fever and arthralgias occurred more fre-
quently than in German travellers with Giardia
infection [14]. Cryptosporidia are an important
and probably under-recognised cause of intestinal
infection in travellers. Diagnostic investigations of
these patients should include methods to detect
cryptosporidia. Risk-factors, including the type
and destination of the journey, should be consid-
ered in pre-travel counselling, especially for
individuals at risk for severe cryptosporidial
infection (e.g., HIV-infected individuals). As the
faecal-oral route is the most frequent route of
cryptosporidial transmission, efforts to reduce
infection should focus on preventive measures
targeting behaviour and hygiene practices.
Table 2. Prevalence of cryptosporidiosis in patients with
travel-associated diarrhoea acquired in different travel
destinations (Institute of Tropical Medicine, Berlin, 2000–
2004)
Geographical
area
Patients with travel-associated diarrhoea
With
cryptosporidiosis
n
Without
cryptosporidiosis
n
Prevalence of
cryptosporidiosis
% 95% CIa
Total 53b 1754 2.9 2.2–3.8
Asia 30 750 3.8 2.6–5.4
South-central Asia 21 359 5.5 3.5–8.3
South-eastern Asia 6 312 1.9 0.7–4.1
Western Asia 3 61 4.7 1.0–13.1
Eastern Asia 0 18 0
Africa 9 607 1.5 0.7–2.8
Eastern Africa 2 166 1.2 0.1–4.2
Western Africa 3 155 1.9 0.4–5.4
Northern Africa 3 191 1.5 0.3–4.5
Middle Africa 1 39 2.5 0.1–13.2
Southern Africa 0 56 0
Latin America 11 363 2.9 1.5–5.2
South America 6 160 3.6 1.3–7.7
Central America 3 133 2.2 0.5–6.3
Caribbean 2 70 2.8 0.3–9.7
Oceania 0 6 0
aExact binominal confidence intervals.
bFour patients presenting without diarrhoea were excluded.
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A C K N O W L E D G E M E N T S
This study was presented, in part, at the 8th Kongress fu¨r
Infektionskrankheiten und Tropenmedizin (Hamburg, 2005).
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A B S T R A C T
This study investigated the seroprevalence of
antibodies against Anaplasma phagocytophilum in
Berlin ⁄Brandenburg, north-eastern Germany.
During 1994–2001, 422 sera from patients with
proven tick-exposure (specimens with antibodies
against Borrelia burgdorferi) were compared with
249 control sera. Using indirect fluorescent anti-
body testing, significantly more positive samples
were detected among Borrelia antibody-positive
specimens (4.5%, 95% CI 2.5–6.5%) than among
controls (1.2%, 95% CI 0.5–1.9%; p < 0.05). While
six (2.2%, 95%CI 1.3–3.1%) samples were positive
among Borrelia antibody-positive sera between
1994 and 1997, 13 (8.7%, 95% CI 6.9–10.5%) were
positive between 1998 and 2001 (p < 0.01), indica-
ting an uneven annual seroprevalence.
Keywords Anaplasma phagocytophilum, annual distri-
bution, diagnosis, human granulocytic anaplasmosis,
seroprevalence, tick-borne disease
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